{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-24-000029","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.534782+00:00","generated_at":"2026-06-05T12:29:01.789445+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcutis Q4 2023 revenue $13.5M (+357% YoY), net loss $66.3M; ZORYVE foam launched","bullets":["Q4 net product revenue $13.5M vs $3.0M Q4 2022, driven by 67% sequential demand growth and GTN improvement.","Full-year 2023 total revenue $59.6M (incl. $30.4M Huadong upfront); net loss $262.1M ($3.78/share).","R&D expenses fell 39% to $110.6M; cash & securities $272.8M as of Dec 31, 2023.","FDA approved ZORYVE foam for seborrheic dermatitis Dec 2023; launched Jan 2024.","PDUFA target date July 7, 2024 for roflumilast cream 0.15% in atopic dermatitis."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-24-000029","json":"https://secwatch.observer/filing/0001787306-24-000029.json","markdown":"https://secwatch.observer/filing/0001787306-24-000029.md","text":"https://secwatch.observer/filing/0001787306-24-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000029/0001787306-24-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000029/arqt-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:29:01.789445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"056813d5a6f1ff8608f40d6e53d00c6d273c3dd2","claim":"Arcutis Biotherapeutics, Inc. reported the quarter ended December 31, 2023 results: revenue $13.5 million.","evidence_excerpt":"--- Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • Q4 net product revenues for ZORYVE® (roflumilast) cream 0.3% were $13.5 million, a 357% increase compared to the fourth quarter of 2022 and a 67% increase compared to the third quarter of 2023; driven by sequential improvement in gross-to-net (GTN) in the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000029/0001787306-24-000029-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2023"},{"label":"Revenue","value":"$13.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}